AUS
NZ
UK
CA
USA
IND
Ian Kadish, a director of Integral Diagnostics Limited (ASX:IDX), has boosted his direct shareholding by converting 37,678 short-term incentive (STI) performance rights into fully paid ordinary shares, effective 1 July 2026. This conversion, disclosed through a Change of Director's Interest Notice filed with the ASX, involved no cash payment, consistent with typical performance rights vesting. Kadish's direct shareholding increased from 673,781 to 711,459 shares. Investors monitoring director equity transactions at IDX may view this vesting as a standard yet meaningful alignment of executive remuneration with shareholder interests.<\/p> <\/div>
Key Points<\/h3>
- Company: Integral Diagnostics Limited (ASX:IDX)<\/li>
- Director Ian Kadish converted 37,678 STI performance rights into fully paid ordinary shares on 1 July 2026<\/li>
- Kadish's direct shareholding rose from 673,781 to 711,459 shares<\/li>
- No cash consideration was involved; rights vested at nil cost<\/li>
- Post-transaction, Kadish retains 49,017 STI and 691,224 LTI performance rights<\/li>
- The transaction occurred outside a closed period, requiring no prior clearance<\/li>
- Investors should monitor upcoming vesting events related to remaining STI and LTI rights<\/li>
<\/ul>
<\/div>
Ian Kadish's Direct Shareholding in Integral Diagnostics Increases Following STI Rights Vesting<\/h2>
On 1 July 2026, Integral Diagnostics director Ian Kadish saw his direct shareholding rise after 37,678 STI performance rights vested and converted into fully paid ordinary shares. Previously holding 673,781 shares directly, Kadish's stake grew to 711,459 shares, marking about a 5.6% increase in his direct shareholding.<\/p>
The transaction was a direct interest change with no third-party involvement and involved no cash exchange, as is typical for performance rights vesting events. Such vesting is a common component of executive remuneration at ASX-listed companies, converting rights into shares once performance or service conditions are met.<\/p>
Shareholder-Approved 37,678 STI Rights Vesting on 1 July 2026<\/h2>
The 37,678 STI performance rights that vested on 1 July 2026 were part of a tranche approved by shareholders at the general meeting on 31 October 2025. This tranche was included in Kadish's broader STI Plan entitlement. The relatively brief interval between shareholder approval and vesting aligns with typical short-term incentive structures featuring around a one-year performance period.<\/p>
Before this vesting, Kadish held two STI tranches: 49,017 rights approved on 1 November 2024 and the 37,678 rights approved on 31 October 2025, totaling 86,695 STI rights. Following this vesting, only the 49,017 rights from November 2024 remain outstanding. The company did not disclose specific performance conditions attached to these rights in the update.<\/p>
Kadish Holds 691,224 LTI Performance Rights Across Three Tranches<\/h2>
In addition to STI rights, Kadish holds 691,224 long-term incentive (LTI) performance rights distributed across three tranches approved at separate shareholder meetings: 248,970 rights from 29 November 2023; 327,566 rights from 1 November 2024; and 114,688 rights from 31 October 2025. These LTI rights remain unaffected by the recent vesting.<\/p>
LTI plans generally involve longer vesting periods, often around three years, contingent on meeting financial, operational, or total shareholder return targets. The presence of multiple LTI tranches spanning from late 2023 to late 2025 indicates Kadish's ongoing participation in annual LTI grant cycles, aligning senior leadership incentives with long-term shareholder value. Specific LTI vesting conditions were not disclosed.<\/p>
Nil Cash Consideration as Performance Rights Vesting Carries No Cost to Director<\/h2>
The company confirmed the transaction involved no cash consideration, consistent with performance rights arrangements where shares are granted as remuneration and convert at no exercise price upon vesting if conditions are met. This differs from exercising listed options, which usually require payment of a strike price.<\/p>
This nil-cost vesting is important for investors interpreting director dealings. Unlike on-market share purchases requiring personal capital deployment, vesting reflects satisfaction of pre-established incentive conditions. Nonetheless, the resulting increase in direct share ownership heightens Kadish's economic exposure to IDX's share price, which may interest investors monitoring management-shareholder alignment.<\/p>
Transaction Occurred Outside Closed Period as per ASX Listing Rules<\/h2>
The update confirms the transaction took place outside any ASX closed period, meaning no prior written clearance was necessary. This disclosure supports market integrity by ensuring director dealings do not occur during windows when insiders might possess price-sensitive, non-public information.<\/p>
Closed periods typically precede half-year and full-year financial results releases and other material announcements. The confirmation that this vesting event was outside such periods assures compliance with the company's securities trading policy. Vesting events are usually scheduled in advance and less subject to timing concerns, but closed-period disclosures remain a vital compliance element.<\/p>
Previous Director's Interest Notice for Ian Kadish Dated 22 December 2025<\/h2>
The last notice filed for Ian Kadish was dated 22 December 2025, providing continuity for tracking his IDX securities interests. The roughly six-month gap between that notice and the 1 July 2026 vesting aligns with timelines for the STI rights approved in October 2025.<\/p>
This sequence illustrates Kadish's active participation in Integral Diagnostics' incentive programs over multiple grant cycles. The gradual accumulation of ordinary shares through successive vesting events is common among senior executives in ASX-listed healthcare and diagnostics firms, where equity compensation is a significant component of total remuneration.<\/p>
Integral Diagnostics Operates in Australia and New Zealand’s Medical Imaging Sector<\/h2>
Integral Diagnostics is an ASX-listed provider of radiology and medical imaging services across Australia and New Zealand. Its offerings include MRI, CT, ultrasound, and X-ray services, primarily delivered through a network of radiology clinics. The Australian diagnostics sector attracts investor interest due to demographic trends such as an ageing population, rising demand for non-invasive diagnostics, and ongoing healthcare infrastructure investment.<\/p>
Director equity holdings in healthcare companies like IDX are closely watched by institutional investors as indicators of management confidence in business prospects. Although this vesting event is part of a routine compensation program rather than a discretionary market purchase, the cumulative effect increases Kadish's direct exposure to IDX shares, reinforcing alignment between management and shareholders.<\/p>
Remaining STI and LTI Rights Indicate Potential Future Vesting Events<\/h2>
Kadish still holds 49,017 STI performance rights from the November 2024 approval, suggesting a possible upcoming STI vesting depending on performance period completion and conditions met. This November 2024 tranche predates the now-vested October 2025 tranche and may be nearing its measurement period end, though the company did not specify exact timelines.<\/p>
The three LTI tranches totaling 691,224 rights, approved between November 2023 and October 2025, represent significant equity exposure. The earliest tranche from November 2023 could be approaching a three-year vesting horizon. Future LTI vesting, if conditions are satisfied, would further increase Kadish’s ordinary shareholding. Specific vesting schedules and performance hurdles were not disclosed.<\/p>
Director Vesting Event’s Immediate Share Price Impact Unclear<\/h2>
Public information does not indicate an immediate share price impact from this vesting event. Such director interest notices are generally regarded as administrative disclosures related to pre-approved remuneration plans rather than material news affecting company performance or strategy. The transaction involved no capital raising, asset acquisitions, or operational guidance.<\/p>
Nonetheless, investors attentive to director dealings may view Kadish’s increased direct shareholding as a modestly positive sign of sustained alignment with shareholders. Market participants focusing on IDX’s equity story will likely await forthcoming operational or financial updates to evaluate underlying fundamentals influencing medium-term share price trends.<\/p>
Ian Kadish's Direct Shareholding in Integral Diagnostics Increases Following STI Rights Vesting<\/h2>
On 1 July 2026, Integral Diagnostics director Ian Kadish saw his direct shareholding rise after 37,678 STI performance rights vested and converted into fully paid ordinary shares. Previously holding 673,781 shares directly, Kadish's stake grew to 711,459 shares, marking about a 5.6% increase in his direct shareholding.<\/p>
The transaction was a direct interest change with no third-party involvement and involved no cash exchange, as is typical for performance rights vesting events. Such vesting is a common component of executive remuneration at ASX-listed companies, converting rights into shares once performance or service conditions are met.<\/p>
Shareholder-Approved 37,678 STI Rights Vesting on 1 July 2026<\/h2>
The 37,678 STI performance rights that vested on 1 July 2026 were part of a tranche approved by shareholders at the general meeting on 31 October 2025. This tranche was included in Kadish's broader STI Plan entitlement. The relatively brief interval between shareholder approval and vesting aligns with typical short-term incentive structures featuring around a one-year performance period.<\/p>
Before this vesting, Kadish held two STI tranches: 49,017 rights approved on 1 November 2024 and the 37,678 rights approved on 31 October 2025, totaling 86,695 STI rights. Following this vesting, only the 49,017 rights from November 2024 remain outstanding. The company did not disclose specific performance conditions attached to these rights in the update.<\/p>
Kadish Holds 691,224 LTI Performance Rights Across Three Tranches<\/h2>
In addition to STI rights, Kadish holds 691,224 long-term incentive (LTI) performance rights distributed across three tranches approved at separate shareholder meetings: 248,970 rights from 29 November 2023; 327,566 rights from 1 November 2024; and 114,688 rights from 31 October 2025. These LTI rights remain unaffected by the recent vesting.<\/p>
LTI plans generally involve longer vesting periods, often around three years, contingent on meeting financial, operational, or total shareholder return targets. The presence of multiple LTI tranches spanning from late 2023 to late 2025 indicates Kadish's ongoing participation in annual LTI grant cycles, aligning senior leadership incentives with long-term shareholder value. Specific LTI vesting conditions were not disclosed.<\/p>
Nil Cash Consideration as Performance Rights Vesting Carries No Cost to Director<\/h2>
The company confirmed the transaction involved no cash consideration, consistent with performance rights arrangements where shares are granted as remuneration and convert at no exercise price upon vesting if conditions are met. This differs from exercising listed options, which usually require payment of a strike price.<\/p>
This nil-cost vesting is important for investors interpreting director dealings. Unlike on-market share purchases requiring personal capital deployment, vesting reflects satisfaction of pre-established incentive conditions. Nonetheless, the resulting increase in direct share ownership heightens Kadish's economic exposure to IDX's share price, which may interest investors monitoring management-shareholder alignment.<\/p>
Transaction Occurred Outside Closed Period as per ASX Listing Rules<\/h2>
The update confirms the transaction took place outside any ASX closed period, meaning no prior written clearance was necessary. This disclosure supports market integrity by ensuring director dealings do not occur during windows when insiders might possess price-sensitive, non-public information.<\/p>
Closed periods typically precede half-year and full-year financial results releases and other material announcements. The confirmation that this vesting event was outside such periods assures compliance with the company's securities trading policy. Vesting events are usually scheduled in advance and less subject to timing concerns, but closed-period disclosures remain a vital compliance element.<\/p>
Previous Director's Interest Notice for Ian Kadish Dated 22 December 2025<\/h2>
The last notice filed for Ian Kadish was dated 22 December 2025, providing continuity for tracking his IDX securities interests. The roughly six-month gap between that notice and the 1 July 2026 vesting aligns with timelines for the STI rights approved in October 2025.<\/p>
This sequence illustrates Kadish's active participation in Integral Diagnostics' incentive programs over multiple grant cycles. The gradual accumulation of ordinary shares through successive vesting events is common among senior executives in ASX-listed healthcare and diagnostics firms, where equity compensation is a significant component of total remuneration.<\/p>
Integral Diagnostics Operates in Australia and New Zealand’s Medical Imaging Sector<\/h2>
Integral Diagnostics is an ASX-listed provider of radiology and medical imaging services across Australia and New Zealand. Its offerings include MRI, CT, ultrasound, and X-ray services, primarily delivered through a network of radiology clinics. The Australian diagnostics sector attracts investor interest due to demographic trends such as an ageing population, rising demand for non-invasive diagnostics, and ongoing healthcare infrastructure investment.<\/p>
Director equity holdings in healthcare companies like IDX are closely watched by institutional investors as indicators of management confidence in business prospects. Although this vesting event is part of a routine compensation program rather than a discretionary market purchase, the cumulative effect increases Kadish's direct exposure to IDX shares, reinforcing alignment between management and shareholders.<\/p>
Remaining STI and LTI Rights Indicate Potential Future Vesting Events<\/h2>
Kadish still holds 49,017 STI performance rights from the November 2024 approval, suggesting a possible upcoming STI vesting depending on performance period completion and conditions met. This November 2024 tranche predates the now-vested October 2025 tranche and may be nearing its measurement period end, though the company did not specify exact timelines.<\/p>
The three LTI tranches totaling 691,224 rights, approved between November 2023 and October 2025, represent significant equity exposure. The earliest tranche from November 2023 could be approaching a three-year vesting horizon. Future LTI vesting, if conditions are satisfied, would further increase Kadish’s ordinary shareholding. Specific vesting schedules and performance hurdles were not disclosed.<\/p>
Director Vesting Event’s Immediate Share Price Impact Unclear<\/h2>
Public information does not indicate an immediate share price impact from this vesting event. Such director interest notices are generally regarded as administrative disclosures related to pre-approved remuneration plans rather than material news affecting company performance or strategy. The transaction involved no capital raising, asset acquisitions, or operational guidance.<\/p>
Nonetheless, investors attentive to director dealings may view Kadish’s increased direct shareholding as a modestly positive sign of sustained alignment with shareholders. Market participants focusing on IDX’s equity story will likely await forthcoming operational or financial updates to evaluate underlying fundamentals influencing medium-term share price trends.<\/p>
